Description
This active molecular is a dihydropyridine Platelet-Activating Factor (PAF) antagonist under the development of Pfizer. In Sep 2015, treatment for Asthma in USA was discontinued. In Sep 2015, Phase-I clinical trials in Dengue in USA was on-going